The US Court of Appeals for the Federal Circuit has thrown out Sanofi’s request to apply the recent Arthrex ruling on the constitutionality of the Patent Trial and Appeal Board (PTAB) to more cases.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
8 January 2026 Crop science division alleges that vaccine developers used patented mRNA stability technology in shots that earned them around $140 billion in global sales.
6 January 2026 The new recruits from a boutique Boston firm enables Merchant to expand and strengthen its tech and life sciences offering in the innovation hub.
